Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
      Description

      This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.

      Conditions
      Squamous Cell Carcinoma of the Head and NeckMelanomaNon Small Cell Lung CancerUrothelial CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the SkinRenal Cell CarcinomaHodgkin LymphomaDiffuse Large B Cell LymphomaMismatch Repair Deficient or MSI-High Solid Tumors
      Talk to us
      RECRUITING
      First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients with Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
      Description

      The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-559 in patients with advanced solid tumors and molecularly defined cancers.

      Conditions
      Advanced Solid TumorsBreast Cancer RecurrentColorectal Cancer MetastaticColon CancerRectal AdenocarcinomaEndometrial Cancer
      Talk to us